Great post wookie. I particularly like hearing an insider say...
____________________________________________________
...there is no indication in any of our seven bavituximab clinical trials to date of any serious allergic reactions and at this point we do not expect to see any. While it is true that chimeric antibodies in theory have a higher risk of generating an allergic or immune response to the antibody itself, in most instances these reactions have proven to be no more than a minor issue. Our preclinical fully human PS-targeting antibodies would be expected to be less likely to generate this type of unwanted immune response, but as noted, it is really not an issue in any case.
____________________________________________________
And go Phillies!
Market Data 
Markets 
AI
